Clinical Trials Logo
  1. Home
  2. Depression, Bipolar
  3. NCT00191399

Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response

Depression, Bipolar Clinical Trial

Official title:
Bipolar Depression Assessment Study on Tx Response

Clinical Trial Summary

The primary objective of this study is to assess the efficacy of olanzapine and fluoxetine combined on all the visits as compared with the baseline visit in patients with bipolar disorder, measured by the total score of the Montgomery-Asberg Depression Rating Scale (MADRS).

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00191399
Study type Interventional
Source Eli Lilly and Company
Contact
Status Completed
Phase Phase 4
Start date May 2004
Completion date March 2006
View Details
See also
  Status Clinical Trial Phase
Completed NCT04469322 - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression N/A
Not yet recruiting NCT05958940 - BioClock: Bright Light Therapy for Depressive Disorders N/A
Recruiting NCT02919280 - Dallas 2K: A Natural History Study of Depression
Completed NCT00060489 - Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression Phase 3
Recruiting NCT05767073 - LIVES: Personalized Lifestyle Intervention for Patients With Depression N/A
Completed NCT04121091 - Pramipexole to Target "Anhedonic Depression" Phase 2
Recruiting NCT04057378 - Optimal Electrical Stimulus During Electroconvulsive Therapy Phase 4
Completed NCT03287037 - The Effects of tDCS on Depressive Symptoms,Neurocognitive Function and HRV in Unipolar Depression and Bipolar Depression N/A
Completed NCT00483548 - Adjunctive Ziprasidone in the Treatment of Bipolar I Depression Phase 3
Not yet recruiting NCT05568823 - Biomarkers of ANTidepressant RESponse and Development Risk of Bipolar Disorder N/A
Recruiting NCT05436613 - Transcranial Direct Current Stimulation Therapy for Bipolar Depression N/A
Completed NCT03538275 - Chronobiology and Depression: Circadian Analytics as a Biomarker for Depressive Subtypes
Recruiting NCT04846010 - Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 Phase 1/Phase 2
Withdrawn NCT02625779 - Combined Cytidine and Creatine-containing Drug in the Treatment of the Bipolar Depression Phase 2
Not yet recruiting NCT06462196 - Natural History of Depression, Bipolar Disorder and Suicide Risk
Recruiting NCT02778256 - Study of the Effectiveness of Vestibular Stimulation Treatment in the Depressive Phase of Bipolar Disorder N/A
Active, not recruiting NCT04643210 - Management of my Bipolarity Intervention in Bipolar Disorder Patients N/A
Completed NCT01396447 - Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression Phase 2
Enrolling by invitation NCT02827045 - Study of a Vestibular Biomarker of Phase in Bipolar Disorder
Completed NCT01898429 - Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD) N/A